Longevity clinics cannot yet prove they extend life. Healthspan can be measured.
Longevity is a promise. Restored health can be measured.
No clinic has demonstrated that its programme adds years to an individual human life. MediBalans therefore begins where the claim becomes testable: with people who have already lost health. We investigate whether impaired function, persistent symptoms and disturbed physiology can be restored — and whether that recovery can be measured and maintained.
This is not proof of a longer lifespan. It is the most honest place for longevity medicine to begin.
No commercial longevity clinic — including this one — has demonstrated that its programme adds years to an individual human life. What can be demonstrated today is health restoration: whether a person who has lost function regains it, by how much, and whether the recovery persists. That is the measurable foundation of healthspan, and it is what MediBalans measures.
The first proof of longevity is restored health
Longevity is usually discussed as a future outcome: more years, slower ageing or a younger biological age. The difficulty is that these promises cannot be verified within the period in which they are sold.
A person may receive an epigenetic age result, change a supplement programme and obtain a different score several months later. The change may contain useful biological information. It does not demonstrate that the person will live longer.
MediBalans takes a different position. Before discussing additional years of life, we ask a more immediate question: can a person who has already lost health regain it? Can persistent fatigue improve? Can gastrointestinal function return? Can pain, metabolic dysfunction or autonomic disturbance be reduced? Can the patient sleep, think, move, work, eat and participate in life more fully?
These are not predictions about a distant future. They are changes that can be assessed in the present. A recovered ability to live is not the same as proof of a longer life. It is, however, the first directly observable component of healthspan.
We do not begin by estimating how many years a person may gain. We begin by measuring how much health has already been lost — and whether it can be restored.
Lifespan, healthspan and health restoration are not the same claim
Lifespan is the total length of a person's life. Healthspan is the period of life during which that person retains meaningful physical, cognitive, metabolic and social function without disabling symptoms, disease burden or dependency. Health restoration is the process of recovering function that has already been lost.
These three outcomes require different levels of evidence. We grade them explicitly.
MediBalans measures health restoration today and follows whether that recovery is preserved. We treat healthspan extension as a hypothesis to be tested — not as a promise to be sold.
What healthspan means at MediBalans
Healthspan is not one blood test, one scan or one biological age number. It is evaluated across three connected layers: how the patient feels, how the patient functions, and what the underlying biology shows.
A laboratory marker may help explain why a patient is unwell. It may guide treatment and demonstrate that a biological process has changed. But the marker is not the patient. The outcome is whether the person can live with greater energy, clarity, resilience, independence and freedom from disabling symptoms.
Biomarkers help us understand recovery. They do not replace it.
Layer one — the person
The patient's lived health. Depending on the condition this may include fatigue and post-exertional capacity, gastrointestinal symptoms and food tolerance, pain and stiffness, sleep and recovery, cognitive clarity, mood and neurological symptoms, ability to work, ability to exercise and move, independence in daily life, social participation, medication burden, relapse frequency and overall quality of life.
These outcomes matter because healthspan is not simply the absence of an abnormal laboratory result. It is the continued ability to live.
Layer two — functional capacity
What the body can objectively do: body composition, skeletal muscle mass, grip strength, sit-to-stand performance, mobility and balance, cardiorespiratory capacity, heart rate variability, orthostatic response, sleep and activity patterns, cognitive performance and condition-specific functional assessments.
A patient who says that energy has returned should, where appropriate, gradually be able to tolerate more activity. A patient recovering from prolonged inactivity should be able to rebuild muscle and physical function. No individual measurement defines healthspan; the value lies in reading the measures together.
Layer three — biological mechanisms
The biological constraints that may be preventing recovery: standard clinical laboratory testing, metabolic and inflammatory markers, gastrointestinal and microbiome assessment, nutrient status, intracellular micronutrient assessment, one-carbon metabolism and homocysteine, immune reactivity, genomic analysis, pharmacogenomics, transcriptomic profiling, autonomic measurement and body composition analysis.
These investigations are not ordered as a catalogue of abnormalities. They are interpreted as a system. The purpose is to identify which dysfunction is most likely to be limiting recovery, which findings are secondary adaptations, and which intervention should come first.
Why chronic illness is the most honest place to test the idea
Many longevity programmes begin with people who already feel well. A healthy client undergoes extensive testing. A number is identified as suboptimal. Supplements, dietary changes or other interventions are prescribed. The test is repeated, and a biomarker moves.
The difficulty is determining what the movement means. Did the person become meaningfully healthier? Was function improved? Was disease prevented? Was lifespan altered? Or did the result reflect normal variation, laboratory variation, sleep, stress, recent exercise or regression toward the average?
In a healthy person, there may be little lost function to restore and little clinical change to observe. Chronic illness presents a more demanding test. The patient begins with a demonstrable loss of health, so improvement must appear not only on a report, but in the patient's life.
A large baseline disturbance makes change easier to detect. It does not automatically prove that treatment caused the change — natural fluctuation, concurrent treatments and regression toward the mean must still be considered. It does, however, make the clinical question much clearer: was lost health restored, by how much, and did the recovery persist?
Healthy-person longevity programmes often infer a future benefit from small biomarker changes. MediBalans investigates whether measurable loss of health can be reversed in the present.
The Global Constraint Rule
The Global Constraint Rule is a MediBalans clinical framework: a complex biological system is limited by the most consequential unresolved constraint acting within it, not by its most visible symptom. The presenting symptom is frequently a compensation for dysfunction elsewhere in the system. The purpose of investigation is therefore not to catalogue abnormalities but to determine which one is currently limiting recovery — and to correct that constraint first.
This is not presented as a universally proven hierarchy for every disease. It is a MediBalans clinical model: a testable method for sequencing investigation and treatment. The dominant constraint differs between patients, and once one constraint improves the system may reorganise and another may become limiting. That is why reassessment is not optional.
Identify. Sequence. Reassess.
Identify — find the most clinically important constraint rather than treating every abnormal result equally. Sequence — begin with the intervention most likely to permit the rest of the system to respond. Reassess — measure what changed, what did not change, and what has become limiting next.
If a programme cannot tell you what should change, by when, and what it means if it does not, it is not measuring recovery.
What the measurements show
Fifty patients, ages 28 to 78, across twelve clinical phenotypes including irritable bowel syndrome, post-viral fatigue, metabolic syndrome, autoimmune conditions, hypertension and type 2 diabetes. Three measurement points: baseline, approximately ninety days, and approximately six months. All body composition measurements by bioelectrical impedance analysis. This is an observational series, not a controlled trial.
Patients who responded well showed larger changes across every layer simultaneously — phase angle rising, visceral fat falling, skeletal muscle increasing, heart rate variability recovering. In poor responders the same measures moved minimally or not at all. That coherence across independent instruments is what distinguishes a systemic change from a single biomarker shift.
Twelve patients did not respond as expected. Their data is included. Non-response is clinically informative: in each case it redirected investigation toward a constraint that had not yet been identified.
Mean values, baseline to final assessment. Weight decreased by a mean of 4.3 kg while skeletal muscle mass increased, indicating that loss was predominantly fat mass rather than lean tissue. Homocysteine was unchanged at ninety days and fell at six months, consistent with the time course of gene-guided methylated cofactor repletion. Observational data from routine clinical practice; no control group, and causality is not established.
What recovered health looks like
Independent patient reviews of MediBalans repeatedly describe outcomes that belong to healthspan rather than to abstract longevity: reduced gastrointestinal symptoms, improved tolerance of food, relief from reflux and digestive distress, greater energy, improved sleep, reduced pain and stiffness, increased mobility, rebuilding muscle after prolonged inactivity, improved metabolic control, greater ability to work and manage daily life, more freedom to travel and eat socially, and a clearer understanding of their health.
These accounts are patient-reported experiences. They are not controlled trials, and they do not prove that every improvement was caused by one specific intervention. They do not demonstrate extended lifespan. They do show what restored health means to the people experiencing it.
For someone previously unable to tolerate ordinary food, health may mean being able to eat with family again. For someone living with severe fatigue, health may mean returning to work or walking without prolonged exhaustion. For someone limited by pain or inactivity, health may mean rebuilding strength and independence. This is why healthspan must be measured in human capability, not only in laboratory values.
What we measure — and what each measurement can prove
Each instrument is graded on its own evidence rather than averaged into a single claim.
Heart rate variability
- What it measures
- Patterns in autonomic regulation and recovery.
- How we use it
- Longitudinally, alongside symptoms, sleep, activity, medication and clinical context. See HRV analysis.
- What it does not prove
- An improvement in HRV alone does not prove extended lifespan.
Body composition and phase angle
- What it measures
- Changes in muscle mass, fat mass, body water and selected indicators of cellular and metabolic status.
- How we use it
- To follow physical recovery, nutritional status and changes in muscle and metabolic composition. See body composition analysis.
- What it does not prove
- A change in body composition does not by itself establish the cause of improvement or predict an individual lifespan.
ALCAT cellular immune reactivity testing
- What it measures
- Selected cellular responses to foods, additives or other substances, measured by leukocyte response. It is not an IgE allergy test and should not be interpreted as one.
- How we use it
- In selected patients and in combination with symptoms, dietary history and clinical reassessment. See ALCAT test.
- Evidence boundary
- The published evidence is condition-specific and limited. It should not be treated as universally validated for all diseases or all individuals.
One-carbon metabolism and methylation
- What it measures
- Genetic and functional factors, assessed across a 38-gene panel, involved in folate metabolism, methionine cycling, transsulfuration and related pathways.
- How we use it
- Genetic findings are interpreted alongside homocysteine, folate, B12, renal function, medication, diet and the wider clinical picture. See methylation test.
- What it does not prove
- A single genetic variant does not diagnose impaired methylation and should not determine treatment in isolation.
Intracellular micronutrient assessment
- What it measures
- Selected nutrient status within cells rather than only circulating serum concentrations.
- How we use it
- As functionally informative data, interpreted alongside standard laboratory results, diet, absorption and clinical presentation. See cellular micronutrient analysis.
- Evidence boundary
- The clinical rationale is stronger than the independent comparative-outcome evidence. It should not be presented as a fully validated standalone diagnostic endpoint.
Genomic and transcriptomic profiling
- What it measures
- Inherited variation and, where transcriptomic testing is used, patterns of current gene expression.
- How we use it
- To understand pathway susceptibility, medication response and biological context.
- What it does not prove
- A genomic or transcriptomic finding is not destiny and does not establish that an intervention will extend life.
Biological age testing
- What it measures
- A statistical estimate derived from molecular patterns associated with chronological age, disease risk, mortality risk or pace of ageing, depending on the model.
- What it may tell us
- Some clocks contain meaningful population-level information and may predict health risk independently of chronological age. See biological age.
- What it cannot prove
- A reduction in an individual biological age score has not been established as proof that an intervention added corresponding years to that person's life.
Where our evidence stops
Anyone working in longevity medicine should state this clearly.
What we can measure
Changes in symptoms, daily function, physical capacity, body composition, selected physiological systems and clinical biomarkers. Whether these changes are coherent across several layers. Whether improvement persists.
What we observe clinically
Some patients demonstrate substantial improvements in symptoms, function and physiological measures. Some improve partially. Some do not improve as expected. Some are unable to complete the programme. Some experience setbacks or adverse effects that require reassessment. Every patient matters, including those who do not improve.
What we hypothesise
That restoring impaired biological systems and maintaining recovered function may improve the probability of preserving health over time; and that several losses of resilience seen in chronic illness overlap with processes that become more common during ageing. This does not mean chronic illness and ageing are identical. It means chronic illness may make certain losses of regulation, resilience and function visible earlier in life.
What we have not proved
We have not proved that every patient will recover. We have not proved that every changed biomarker produces a meaningful clinical benefit. We have not proved that MediBalans treatment prevents every future disease. We have not proved that it adds years to human life. No clinic currently has.
We measure health restoration today, follow healthspan preservation over time and leave lifespan extension where it belongs: as an unanswered scientific question.
The MediBalans healthspan standard
A credible healthspan programme should be able to answer seven questions.
- What health has the person lost? The starting impairment must be defined in symptoms, function or clinical findings.
- What is the proposed biological constraint? The treatment must be connected to a coherent clinical hypothesis.
- What is the intervention expected to change? The expected outcome must be specified before reassessment.
- When should change occur? Different biological systems recover at different rates. The timeline should be clinically plausible and stated in advance.
- How will recovery be measured? Patient experience, functional capacity and biological markers should be assessed together.
- What will failure mean? If the patient does not improve, the hypothesis must be reconsidered rather than protected.
- Did the improvement persist? A temporary response is not the same as restored healthspan.
This is the standard we believe longevity medicine should meet.
Common questions
Our position
MediBalans does not sell predicted years of life. We work at the point where healthspan becomes directly observable: where health and function have already been lost. We investigate why the system is failing. We identify the most important constraint. We sequence the intervention. We measure whether the patient feels better, functions better and demonstrates corresponding physiological recovery. We follow whether that recovery persists.
This is health restoration: the immediately measurable foundation of healthspan. Whether it ultimately produces additional healthy years — or additional years of life — must be answered through long-term evidence. Until then, honesty requires us to distinguish what we can measure from what we merely hope.
Selected references
- Ali A, Weiss TR, McKee D, et al. Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial. BMJ Open Gastroenterology. 2017;4:e000164.
- Castro-Marrero J, et al. Comorbidity in chronic fatigue syndrome and heart rate variability. Journal of Translational Medicine. 2020;18:4.
- Yamagishi JF, Hatakeyama TS. Global constraint principle for microbial growth laws. Proceedings of the National Academy of Sciences. 2025;122(40):e2515031122. doi:10.1073/pnas.2515031122.
- Meyer DH, Schumacher B. BiT age: a transcriptome-based ageing clock. Aging Cell. 2021;20(3):e13320.
- Crider KS, et al. Folate and DNA methylation: a review of molecular mechanisms. Advances in Nutrition. 2012;3(1):21–38.
- Hickey SE, et al. ACMG practice guideline: lack of evidence for MTHFR polymorphism testing. Genetics in Medicine. 2013;15(2):153–156.
- World Health Organization. Healthy ageing and functional ability.
- MediBalans. Independently published patient reviews on Reco.
Editorial transparency
- Written by
- Dr Mario Anthis, Founder and Medical Director, MediBalans
- Medically reviewed by
- Dr Christina Biri, MD, PhD, Specialist in General Medicine and Cardiology
- First published
- 21 July 2026
- Last evidence review
- 21 July 2026
- Next scheduled review
- 21 July 2027
This page describes the MediBalans clinical framework and the evidence supporting its components. It does not guarantee individual outcomes. All investigations and protocols require individual clinical assessment.